PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
April 19 2023 - 8:30AM
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage
biopharmaceutical company focusing on the development of novel
anti-purinergic drug therapies (“APT”) for the treatment of
disorders with intractable neurologic symptoms, today announced
that Chief Executive Officer Howard Weisman will ring the Nasdaq
Stock Market closing bell on Wednesday April 19, 2023. This comes
to celebrate PaxMedica’s listing of its common shares on the Nasdaq
Capital Market in August 2022 and April’s Autism Awareness Month.
The live broadcast will start at 3:45 PM Eastern Time on April
19, 2023 from the Nasdaq MarketSite Tower in New York City, New
York. Please tune in to the broadcast by visiting
https://livestream.com/accounts/27896496/events/10809459
Howard Weisman, Chief Executive Officer of PaxMedica, commented,
“I am honored to ring the Nasdaq bell on behalf of the entire
PaxMedica team. We’ve worked hard to reach this important market
milestone, and to be here during Autism Awareness Month is a
poignant reminder of the enormous clinical need for new treatment
modalities. Thank you to the Nasdaq team for the recognition and
opportunity and to all of those who have helped us on our journey.
We appreciate everyone’s support as we advance on our mission to
develop treatments for disorders with intractable neurologic
symptoms, such as autism spectrum disorder.”
About PaxMedica
PaxMedica is a clinical stage biopharmaceutical
company focusing on the development of anti-purinergic drug
therapies (“APT”) for the treatment of disorders with intractable
neurologic symptoms, ranging from neurodevelopmental disorders,
including Autism Spectrum Disorder (“ASD”), to Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a
debilitating physical and cognitive disorder believed to be viral
in origin and now with rising incidence globally due to the long
term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary
points of focus is the development and testing of its lead program,
PAX-101, an intravenous formulation of suramin, in the treatment of
ASD and the advancement of the clinical understanding of using that
agent against other disorders such as ME/CFS and Long COVID-19
Syndrome, a clinical diagnosis in individuals who have been
previously infected with COVID-19.
Forward-Looking Statements
This press release contains “forward-looking
statements.” Forward-looking statements reflect our current view
about future events. Investors can identify these forward-looking
statements by words or phrases such as “may,” “will,” “could,”
“expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “is/are likely to,” “propose,” “potential,” “continue”
or similar expressions. These forward-looking statements include
our anticipated clinical program, the timing and success of our
anticipated data announcements, pre-clinical and clinical trials
and regulatory filings, statements about the strength of our
balance sheet. These forward-looking statements involve known and
unknown risks and uncertainties and are based on the Company’s
current expectations and projections about future events that the
Company believes may affect its financial condition, results of
operations, business strategy and financial needs. Such risks and
uncertainties include, but are not limited to, risks associated
with the Company’s development work, including any delays or
changes to the timing, cost and success of the Company’s product
development and clinical trials, risk of insufficient capital
resources, cash funding and cash burn and risks associated with
intellectual property and infringement claims. The Company
undertakes no obligation to update or revise publicly any
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review those other risks and uncertainties
described in the section titled "Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 2022 and other reports
as filed with the SEC.
Contacts:
ir@paxmedica.com
Stephanie PrincePCG Advisorysprince@pcgadvisory.com(646)
863-6341
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024